Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
EMBCthis companyEmbecta Corp.	$6.17	8.6×	-1.26×	0.76×	7.13×	437.2%	62.9%	30.5%	8.8%	-14.6%	27.4%	22.2%	-2.2×	4.24×	3.07×	2.41×	4.3%	6	1.32	3	B
AQSTAquestive Therapeutics, Inc.	$3.49	-8.5×	-23.41×	17.69×	-12.07×	-157.6%	61.5%	-156.4%	-188.1%	248.9%	-56.0%	-6.7%	-3.9×	-0.16×	-4.07×	3.14×	0.0%	3	-3.77	2	C
CDNACareDx, Inc	$84.90	-47.1×	3.31×	2.64×	-207.24×	-113.5%	67.6%	-6.6%	-5.6%	-7.0%	-7.6%	3.6%	0.09×	8.43×	0×	2.86×	0.0%	6	15.65	3	B+
EBSEmergent BioSolutions Inc.	$6.04	12.61×	1.27×	0.89×	4.32×	-48.4%	47.2%	14.8%	7.1%	10.1%	5.9%	23.7%	1.09×	1.54×	1.86×	5.01×	0.0%	4	0.4	1	C-
EVHEvolent Health, Inc.	$4.54	-0.79×	1.1×	0.24×	-3.58×	-2363.6%	15.1%	-0.2%	-28.5%	-128.7%	-0.3%	1.0%	2.38×	-2.32×	-0.08×	1.31×	2.4%	5	-0.38	2	C+
MRVIMaravai LifeSciences Holdings, Inc.	$8.00	-3.57×	2.22×	2.54×	-4.86×	-66.3%	18.0%	-3.6%	-70.4%	-61.6%	-0.9%	-15.0%	0.17×	1.23×	-0.25×	6.6×	0.0%	4	4.88	1	C-
Peer median	—	-3.57×	1.27×	2.54×	-4.86×	-113.5%	47.2%	-3.6%	-28.5%	-7.0%	-0.9%	1.0%	0.17×	1.23×	-0.08×	3.14×	0.0%	4	0.4	2	—